Advertisement

Identification of the Pathogenic Biomarkers for Hepatocellular Carcinoma Based on RNA-seq Analyses

  • Wentao JiangEmail author
  • Li Zhang
  • Qingjun Guo
  • Honghai Wang
  • Ming Ma
  • Jisan Sun
  • Chiyi Chen
Original Article
  • 44 Downloads

Abstract

The purpose of this study was to explore potential biomarkers in the diagnosis of hepatocellular carcinoma (HCC) based on RNA-seq. The microarray data GSE98269 were downloaded from the GEO database, including the miRNA, mRNA and lncRNA expression profiles of 3 HCC tissues and 3 normal liver tissues from 3 HCC patients. The limma package was used to identify the differentially expressed miRNAs (DEMs) and the differentially expressed lncRNAs in HCC tissues compared with normal liver tissues. Database of DAVID, KEGG PATHWAY and Reactome were used to perform the functional and pathway enrichment. Putative targets for DEMs, and the miRNA-gene pairs were predicted via the miRWalk V2.0 database. The protein-protein pairs of DEGs were screened via String software. The expression features of the differentially expressed lncRNAs were analyzed. The regulated network of DEGs and DEMs were constructed, and related genes and miRNAs were detected in the HCC tissues and normal liver samples with Q-PCR. A total of 678 DEGs, 32 DEMs and 411 differential expressed lncRNAs were identified. The DEGs were enriched in 196 GO terms and 79 pathways. 38 negative regulation miRNA-gene pairs and 1205 protein-protein interactions were screened out, and the regulated network was constructed based on them. KNG1, CDK1, EHHADH, CYP3A4, hsa-miR-199a-5p and hsa-miR-455-3p might be biomarkers in the occurrence of HCC.

Keywords

Hepatocellular carcinoma (HCC) Early diagnosis RNA-seq 

Notes

Acknowledgements

We would like to thank all the members of our research group for their enthusiastic participation in this study.

Funding

Tianjin Clinical Research Center for Organ Transplantation (Grant No.15ZXLCSY00070); International Science and Technology Cooperation Program of China (Grant No. 2015DFG31850); National Key Clinical Specialty Construction Project of Organ Transplantation Department (Grant No.2013544); Science and Technology Fund of Tianjin Municipal Health Bureau (Grant No. 2013 KZ034); The study of precisely medical technology in the perioperative period of liver transplantation for liver cancer (Grant No. 17ZXMFSY00040); Spring Buds Project (Grant No. CL201801); General Program of The National Natural Science Foundation of China (Grant No. 81870444); Trial Registration Clinical Trial Registration URL: http://www.chictr.org.cn/showproj.aspx?proj=19662 webcite Trial Registration number: ChiCTR-ROR-17012157.

Compliance with Ethical Standards

Competing Interests

The authors declare that they have no competing interests.

References

  1. 1.
    McGuire S (2016) World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Advances in Nutrition (Bethesda, Md) 7:418–419CrossRefGoogle Scholar
  2. 2.
    Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer 136:E359–E386Google Scholar
  3. 3.
    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(9):7–30CrossRefGoogle Scholar
  4. 4.
    Diaz-Gonzalez A, Forner A, Rodriguez de Lope C, Varela M (2016) New challenges in clinical research on hepatocellular carcinoma. Revista Espanola De Enfermedades Digestivas : Organo Oficial De La Sociedad Espanola De Patologia Digestiva 108:485–493Google Scholar
  5. 5.
    Li D, Satomura S (2015) Biomarkers for hepatocellular carcinoma (HCC): an update. Adv Exp Med Biol 867:179–193CrossRefGoogle Scholar
  6. 6.
    Kiyokawa H, Yasuda H (2017) Serum Monomeric Laminin-Gamma2 as a Novel Biomarker for Hepatocellular Carcinoma. Cancer Science 108:1432–1439Google Scholar
  7. 7.
    Shaker O, Alhelf M, Morcos G, Elsharkawy A (2017) miRNA-101-1 and miRNA-221 expressions and their polymorphisms as biomarkers for early diagnosis of hepatocellular carcinoma. Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 51:173–181CrossRefGoogle Scholar
  8. 8.
    Shen Q, Fan J, Yang XR et al (2012) Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol 13:817–826CrossRefGoogle Scholar
  9. 9.
    Huang S, Jiang F, Wang Y et al (2017) Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients. Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine 39:1010428317705763Google Scholar
  10. 10.
    Saitta C, Raffa G, Alibrandi A et al (2017) PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. Medicine 96:e7266CrossRefGoogle Scholar
  11. 11.
    Iarovaia GA (2001) Kallikrein-kinin system: novel facts and concepts (literature review). Vopr Med Khim 47:20–42Google Scholar
  12. 12.
    Colman RW (2006) Regulation of angiogenesis by the kallikrein-kinin system. Curr Pharm Des 12:2599–2607CrossRefGoogle Scholar
  13. 13.
    Quesada-Calvo F, Massot C, Bertrand V et al (2017) OLFM4, KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early colorectal cancer stages. Clin Proteomics 14:9CrossRefGoogle Scholar
  14. 14.
    Ren Y, Ji N, Kang X et al (2016) Aberrant ceRNA-mediated regulation of KNG1 contributes to glioblastoma-induced angiogenesis. OncotargetGoogle Scholar
  15. 15.
    Cho SJ, Lee SS, Kim YJ et al (2010) Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo. Cancer Lett 287:196–206CrossRefGoogle Scholar
  16. 16.
    Luo HB, Chen GW, Shao YX, Li Z, Liu M, Liu PQ (2012) 3D-QSAR studies on pyrimidine analogues as cyclin-dependent kinase 1 inhibitors. Shenzhen Daxue Xuebao 29:438–443Google Scholar
  17. 17.
    Zhao J, Han SX, Ma JL et al (2013) The role of CDK1 in apoptin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep 30:253–259CrossRefGoogle Scholar
  18. 18.
    Yi Z, Wei H, Yan R et al (2015) miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3. Tumor Biol 36:8309–8316CrossRefGoogle Scholar
  19. 19.
    Baes M, Van Veldhoven PP (2016) Hepatic dysfunction in peroxisomal disorders. BBA - Molecular Cell Research 1863:956–970Google Scholar
  20. 20.
    Houten SM, Denis S, Argmann CA (2012) Peroxisomal L-bifunctional enzyme (Ehhadh) is essential for the production of medium-chain dicarboxylic acids. J Lipid Res 53:1296–1303CrossRefGoogle Scholar
  21. 21.
    Suto K, Kajihara-Kano H, Yokoyama Y et al (1999) Decreased expression of the peroxisomal bifunctional enzyme and carbonyl reductase in human hepatocellular carcinomas. J Cancer Res Clin Oncol 125:83–88CrossRefGoogle Scholar
  22. 22.
    Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–141CrossRefGoogle Scholar
  23. 23.
    Ali GT, Al-Azhary NM, Mokhtar DA (2014) Frequency and prognostic significant of CYP3A4-a-290G polymorphism in acute myeloid leukemia. J Adv Res 5:657–661CrossRefGoogle Scholar
  24. 24.
    Rodrigues RM, De Kock J, Doktorova TY, Rogiers V, Vanhaecke T (2015) Measurement of cytochrome P450 enzyme induction and inhibition in human hepatoma cells. Methods Mol Biol 1250:279–285CrossRefGoogle Scholar
  25. 25.
    Williams AE (2008) Functional aspects of animal microRNAs. Cell Mol Life Sci 65:545–562CrossRefGoogle Scholar
  26. 26.
    Eulalio A, Huntzinger E, Nishihara T, Rehwinkel J, Fauser M, Izaurralde E (2009) Deadenylation is a widespread effect of miRNA regulation. RNA (New York, NY) 15:21–32CrossRefGoogle Scholar
  27. 27.
    Hawkins PG, Morris KV (2008) RNA and transcriptional modulation of gene expression. Cell cycle (Georgetown, Tex) 7:602–607CrossRefGoogle Scholar
  28. 28.
    Schultz S, Neubauer H, Bartsch H et al (2014) Hsa-miR-199a-5p is functionally relevant in progression from ductal carcinoma in situ to invasive breast tumours. Oncology Research & Treatment 37:68–68Google Scholar
  29. 29.
    Shen Q, Cicinnati VR, Zhang X et al (2010) Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer 9:227CrossRefGoogle Scholar
  30. 30.
    Sand M, Skrygan M, Sand D et al (2012) Expression of microRNAs in basal cell carcinoma. Br J Dermatol 167:847–855CrossRefGoogle Scholar
  31. 31.
    Chickooree D, Zhu K, Ram V, Wu HJ, He ZJ, Zhang S (2016) A preliminary microarray assay of the miRNA expression signatures in buccal mucosa of oral submucous fibrosis patients. J Oral Pathol Med 45:691–697CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2019

Authors and Affiliations

  • Wentao Jiang
    • 1
    Email author
  • Li Zhang
    • 1
  • Qingjun Guo
    • 1
  • Honghai Wang
    • 1
  • Ming Ma
    • 1
  • Jisan Sun
    • 1
  • Chiyi Chen
    • 1
  1. 1.Department of Liver Transplantation, Key Laboratory for Critical Care Medicine of the Ministry of Health, Tianjin Key Laboratory for Organ TransplantationTianjin First Center HospitalTianjinPeople’s Republic of China

Personalised recommendations